EGFR and interstitial lung disease: The causative drugs of ILD in the 44 patients were found to be nivolumab (14 patients), EGFR-TKI (gefitinib or erlotinib; 13 patients), trastuzumab plus paclitaxel (7 patients), gemcitabine (3 patients), gemcitabine plus nanoparticle albumin-bound paclitaxel (2 patients), FOLFIRINOX (a combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin; 1 patient), adriamycin plus cyclophosphamide (1 patient), trastuzumab emtasine (1 patient), docetaxel (1 patient), and nanoparticle albumin-bound paclitaxel (1 patient).